Dr. Paul R. Fortin, MD, MPH, FRCPC holds the Tier 1 Canada Research Chair in Systemic Autoimmune Rheumatic Diseases, is Professor at Laval University, and Clinical Investigator at the CHU Research Center of Quebec – Laval University. He obtained his medical degree from Laval University and is a graduate of McGill University in rheumatology. He then obtained a Master’s in Public Health from Harvard University’s School of Public Health.

Dr. Fortin is working to better understand the bio-psycho-social impact of systemic autoimmune rheumatic diseases (SARD), such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, inflammatory myositis, and antiphospholipid syndrome (APS). He is particularly interested in the development of interventions for the treatment of SLE, RA, and APS.

His methodological interests are the development and validation of diagnostic and prognostic tests, new treatments, and new ways to measure the impact of these treatments on the health status of the patient, and on the levels of activity or harm of the disease within SARDs. His other methodological interests include developing healthy lifestyle habits for people with SARD, and measuring the impact of patient knowledge.

Since 2011, Dr. Fortin has been working on the creation and establishment of a new computerized database and biobank that enables the collection of informative biospecimens and clinical data relevant to the study of SARDs. This biobank and database now has more than 13,000 biospecimens, from over 250 people, and has already contributed to translational and clinical research projects, as well as two projects funded by the Canadian Institutes of Health Research.

Dr. Fortin received the Canadian Rheumatology Association (CRA) Young Investigator Award in 1999, the Kirkland Scholar Award in 2008, and the prestigious Research Achievement Award from The Arthritis Society of Canada (2007- 2012). In 2010, he received the Lupus Ontario Hope Award for his outstanding leadership in improving the lives of people with lupus. In May 2015, he received the Jeffrey Shiroky Research Award for his clinical research achievements in rheumatology.

CHUL
2705, boulevard Laurier
T0-97
Québec, Québec
Canada G1V 4G2
390 entries « 1 of 39 »

Huot S, Fortin PR, Godbout A, Laflamme C, Pouliot M

A tool to assist rheumatologists to engage their lupus patients: the Purple Butterfly

Journal Article

Rheumatol Adv Pract, 8 (3), 2024.

Abstract | Links:

Balbi GGM, Ahmadzadeh Y, Tektonidou MG, Pengo V, Sciascia S, Ugarte A, Belmont HM, Lopez-Pedrera C, Fortin PR, Wahl D, Gerosa M, de Jesús GR, Ji L, Atsumi T, Efthymiou M, Branch DW, Nalli C, Rodriguez Almaraz E, Petri M, Cervera R, Knight JS, Artim-Esen B, Willis R, Bertolaccini ML, Cohen H, Roubey R, Erkan D, de Andrade DCO,

Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry

Journal Article

Rheumatology (Oxford), 63 (3), 2024.

Abstract | Links:

Yelnik CM, Erton ZB, Drumez E, Cheildze D, de Andrade D, Clarke A, Tektonidou MG, Sciascia S, Pardos-Gea J, Pengo V, Ruiz-Irastorza G, Belmont HM, Pedrera CL, Fortin PR, Wahl D, Gerosa M, Kello N, Signorelli F, Atsumi T, Ji L, Efthymiou M, Branch DW, Nalli C, Rodriguez-Almaraz E, Petri M, Cervera R, Shi H, Zuo Y, Artim-Esen B, Pons-Estel G, Willis R, Barber MRW, Skeith L, Bertolaccini ML, Cohen H, Roubey R, Erkan D

Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prospective study from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository ("Registry")

Journal Article

Semin Arthritis Rheum, 65 , 2024.

Abstract | Links:

Willett JDS, Gravel A, Dubuc I, Gudimard L, Dos Santos Pereira Andrade AC, Lacasse É, Fortin P, Liu JL, Cervantes JA, Galvez JH, Djambazian HHV, Zwaig M, Roy AM, Lee S, Chen SH, Ragoussis J, Flamand L

SARS-CoV-2 rapidly evolves lineage-specific phenotypic differences when passaged repeatedly in immune-naïve mice

Journal Article

Commun Biol, 7 (1), 2024.

Abstract | Links:

Bowdish DME, Chandran V, Hitchon CA, Kaplan GG, Avina-Zubieta JA, Fortin PR, Larché MJ, Boire G, Gingras AC, Dayam RM, Colmegna I, Lukusa L, Lee JLF, Richards DP, Pereira D, Watts TH, Silverberg MS, Bernstein CN, Lacaille D, Benoit J, Kim J, Lalonde N, Gunderson J, Allard-Chamard H, Roux S, Quan J, Hracs L, Turnbull E, Valerio V, Bernatsky S,

When Should I Get My Next COVID-19 Vaccine? Data From the Surveillance of Responses to COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED) Study

Journal Article

J Rheumatol, 51 (7), 2024.

Abstract | Links:

Krustev E, Hanly JG, Chin R, Buhler KA, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sánchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg D, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri MA, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askenase A, Buyon J, Fritzler MJ, Clarke AE, Choi MY

Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus

Journal Article

Lupus Sci Med, 11 (1), 2024.

Abstract | Links:

Dal Santo T, Rice D, Carrier ME, Virgili-Gervais G, Levis B, Kwakkenbos L, Bartlett SJ, Gietzen A, Gottesman K, Guillot G, Hudson M, Hummers LK, Malcarne V, Mayes M, Mouthon L, Richard M, Sauve M, Wojeck R, Geoffroy MC, Benedetti A, Thombs B,

Factors associated with satisfaction with social roles and activities among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort cross-sectional study

Journal Article

RMD Open, 10 (1), 2024.

Abstract | Links:

Rapoport CS, Choi AK, Kwakkenbos L, Carrier ME, Henry RS, Levis B, Bartlett SJ, Gietzen A, Gottesman K, Guillot G, Lawrie-Jones A, Mayes MD, Mouthon L, Richard M, Worron-Sauvé M, Benedetti A, Roesch SC, Thombs BD, Malcarne VL, ,

Moderators of Loneliness Trajectories in People with Systemic Sclerosis During the COVID-19 Pandemic: A SPIN COVID-19 Cohort Longitudinal Study

Journal Article

Int J Behav Med, 31 (3), 2024.

Abstract | Links:

Barber MRW, Ugarte-Gil MF, Hanly JG, Urowitz MB, St-Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Pons-Estel BA, Cardwell FS, Alarcón GS, Clarke AE

Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

Journal Article

Ann Rheum Dis, 2024.

Abstract | Links:

Habib R, Dayam RM, Hitchon C, Chandran V, Fortin PR, Boire G, Bowdish DME, Gingras AC, Flamand L, Larché MJ, Colmegna I, Lukusa L, Lee JLF, Pereira D, Bernstein CN, Lalonde N, Turnbull E, Bernatsky S,

Duration of Postvaccination Neutralizing Antibodies to SARS-CoV-2 and Medication Effects: Results from the Safety and Immunogenicity of COVID-19 Vaccination in Systemic Immune-Mediated Inflammatory Diseases Cohort Study

Journal Article

ACR Open Rheumatol, 2024, ISSN: 2578-5745.

Abstract | Links:

390 entries « 1 of 39 »
Signaler des ajouts ou des modifications

Active projects

  • Canada research chair in Innovate Systemic Autoimmune Rheumatic Disease, from 2019-07-01 to 2026-06-30
  • FcgRI as a potential therapeutic target in inflammatory arthritis, from 2022-01-01 to 2025-03-31
  • Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, from 2020-04-01 to 2025-03-31
  • Risk stratification and personalized therapy in lupus pregnancies, from 2022-10-01 to 2027-09-30
  • Role of megakaryocytes in Systemic Lupus Erythematosus, from 2023-04-01 to 2028-03-31
  • Role of phosphatidylserine-specific phospholipase A1 (PLA1A) in the pathogenesis of rheumatic diseases, from 2023-01-01 to 2025-12-31

Recently finished projects

  • Booster dose of mRNA SARS-CoV-2 vaccine vs non mRNA vaccine for people living with systemic autoimmune rhumatic diseases without adequate humoral response post standard mRNA vaccination, from 2021-12-01 to 2022-11-30
  • CompreHensive Analysis of Mitochondria in Pathogenesis of SLE (CHAMPS), from 2021-09-01 to 2022-08-31
  • COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases / La réponse immunitaire au vaccin contre la COVID-19 chez des patients immunosupprimés en raison de maladies auto-immunes, from 2021-03-16 to 2023-03-31
  • Hydroxychloroquine in systemic lupus, from 2018-04-01 to 2023-03-31
  • Maladies Rhumatismales Autoimmunes Systémiques (MRAS) , from 2020-12-15 to 2023-03-31
  • Megakaryocyte: a new player in systemic lupus erythematosus, from 2022-09-01 to 2023-08-31
  • Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, from 2020-01-01 to 2022-12-31
  • Role of autotaxin bound to platelet-derived microparticles to development of vascular damage in arthritis., from 2015-07-01 to 2023-03-31
  • Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED) , from 2021-04-01 to 2023-09-30
  • The impact of antimalarial drugs in arthritis patients exposed to SARS-CoV-2- the CoVIRAL project, from 2020-04-01 to 2023-03-31
  • Understanding the pathogenesis of COVID-19, from 2020-03-01 to 2023-02-28
Data provided by the Université Laval research projects registery